Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
In: BMC Cancer, 2024
academicJournal
Zugriff:
Evaluation of human epidermal growth factor receptor 2 (HER2) overexpression caused by erb-b2 receptor tyrosine kinase 2 (ERBB2) amplification (AMP) by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) is essential for treating unresectable metastatic gastric cancer (GC). A targeted tumour sequencing test enables comprehensive assessment of alterations in cancer-related genes, including ERBB2. This study aimed to evaluate the concordance between the targeted tumour sequencing test and IHC/FISH for detecting HER2-positive GC and to clarify the significance of ERBB2 AMP and concomitant genetic alterations in HER2 downstream pathways (DPs) in anti-HER2 therapy for unresectable metastatic GC patients.
Titel: |
Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
|
---|---|
Autor/in / Beteiligte Person: | Ichikawa, Hiroshi ; Usui, Kenji ; Aizawa, Masaki ; Shimada, Yoshifumi ; Muneoka, Yusuke ; Kano, Yosuke ; Sugai, Mika ; Moro, Kazuki ; Hirose, Yuki ; Miura, Kohei ; Sakata, Jun ; Yabusaki, Hiroshi ; Nakagawa, Satoru ; Kawasaki, Takashi ; Umezu, Hajime ; Okuda, Shujiro ; Wakai, Toshifumi |
Link: | |
Zeitschrift: | BMC Cancer, 2024 |
Veröffentlichung: | BioMed Central, 2024 |
Medientyp: | academicJournal |
DOI: | 10.1186/s12885-024-12482-5 |
Schlagwort: |
|
Sonstiges: |
|